순환종양세포 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 검체별, 제품별, 기술별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Circulating Tumor Cells Market Summary

The global circulating tumor cells market size was estimated at USD 14.04 billion in 2025 and is projected to reach USD 38.95 billion by 2033, expanding at a CAGR of 13.92% from 2026 to 2033, owing to the non-invasiveness and advantages offered by circulating tumor cells (CTC), it is considered a promising tool in cancer diagnosis. In addition, technological advancements in chip technology are another key factor driving market growth.

Global Circulating Tumor Cells Market Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global circulating tumor cells market on the basis of technology, application, product, specimen, end use, and region.

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Circulating Tumor Cells CTC Detection & Enrichment Methods
  • Immunocapture (Label-based)
  • Positive Selection
  • Negative Selection
  • Size-based Separation (Label-free)Density-based Separation (Label-free)
  • Membrane-based
  • Microfluidic-based
  • Density-based Separation (Label-free)
  • Combined Methods
• CTC Direct Detection Methods
• CTC Analysis
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical
  • Risk Assessment
  • Screening and Monitoring
• Research
  • Cancer Stem Cell & Tumorogenesis Research
  • Drug/Therapy Development
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Kits & Reagents
• Blood Collection Tubes
• Devices or Systems
• Specimen Outlook (Revenue, USD Million, 2021 - 2033)
• Blood
• Bone Marrow
• Other Body Fluids
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Research and Academic Institutes
• Hospital and Clinics
• Diagnostic Centers
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Application
  • 1.2.3. Product
  • 1.2.4. Specimen
  • 1.2.5. End use
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Circulating Tumor Cells Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advancements in chip technology
    • 3.2.1.2. Expanding applications of CTCs
    • 3.2.1.3. Growing demand for early and rapid cancer diagnosis
    • 3.2.1.4. Growing incidence of cancer
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Consistency-related challenges in CTC detection and enrichment
    • 3.2.2.2. Higher preference for Point-of-Care (POC) testing and nonavailability of POC adaptable CTC tests
    • 3.2.2.3. Lower applicability of CTCs in rare cancers
• 3.3. Circulating Tumor Cells Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Circulating Tumor Cells Market: Technology Estimates & Trend Analysis

• 4.1. Technology Segment Dashboard
• 4.2. Global Circulating Tumor Cells Market Technology Movement Analysis
• 4.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.4.1. CTC Detection & Enrichment Methods
    • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.2. Immunocapture (Label-based)
      • 4.4.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.2.2. Positive Selection
        • 4.4.1.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.2.3. Negative Selection
        • 4.4.1.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.3. Size-based Separation (Label-free)
      • 4.4.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.3.2. Membrane-based
        • 4.4.1.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.3.3. Microfluidic-based
        • 4.4.1.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.4. Density-based Separation (Label-free)
      • 4.4.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.5. Combined Methods
      • 4.4.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. CTC Direct Detection Methods
    • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2.2. SERS
      • 4.4.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2.3. Microscopy
      • 4.4.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2.4. Others
      • 4.4.2.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. CTC Analysis
    • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Circulating Tumor Cells Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Circulating Tumor Cells Market Application Movement Analysis
• 5.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.4.1. Clinical
    • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.1.2. Risk Assessment
      • 5.4.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.1.3. Screening and Monitoring
      • 5.4.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Research
    • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2.2. Cancer Stem Cell & Tumorogenesis Research
      • 5.4.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2.3. Drug/Therapy Development
      • 5.4.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Circulating Tumor Cells Market: Product Estimates & Trend Analysis

• 6.1. Product Segment Dashboard
• 6.2. Global Circulating Tumor Cells Market Product Movement Analysis
• 6.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.4.1. Kits & reagents
    • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Blood collection tubes
    • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. Devices or systems
    • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Circulating Tumor Cells Market: Specimen Estimates & Trend Analysis

• 7.1. Specimen Segment Dashboard
• 7.2. Global Circulating Tumor Cells Market Specimen Movement Analysis
• 7.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Specimen, 2021 to 2033 (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.4.1. Blood
    • 7.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Bone marrow
    • 7.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Other body fluids
    • 7.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Circulating Tumor Cells Market: End Use Estimates & Trend Analysis

• 8.1. End Use Segment Dashboard
• 8.2. Global Circulating Tumor Cells Market End Use Movement Analysis
• 8.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 8.4.1. Research and academic institutes
    • 8.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. Hospital and clinics
    • 8.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. Diagnostic centers
    • 8.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Circulating Tumor Cells Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2025 & 2033
• 9.2. Regional Market Dashboard
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.1.5. Target disease prevalence
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.2.5. Target disease prevalence
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.3.5. Target disease prevalence
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.1.5. Target disease prevalence
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.2.5. Target disease prevalence
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.3.5. Target disease prevalence
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.4.5. Target disease prevalence
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.5.5. Target disease prevalence
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.6.5. Target disease prevalence
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.7.5. Target disease prevalence
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.8.5. Target disease prevalence
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.1.5. Target disease prevalence
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.2.5. Target disease prevalence
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.3.5. Target disease prevalence
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.4.5. Target disease prevalence
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.5.5. Target disease prevalence
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.6.5. Target disease prevalence
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.6.1.5. Target disease prevalence
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.6.2.5. Target disease prevalence
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.7.1.5. Target disease prevalence
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.7.2.5. Target disease prevalence
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.7.3.5. Target disease prevalence
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.7.4.5. Target disease prevalence

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Key company position analysis, 2025
• 10.4. Key Company Profiles
  • 10.4.1. QIAGEN
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Bio-Techne Corp.
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Precision Medicine Group, LLC.
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Bio-Rad Laboratories, Inc.
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Natera, Inc.
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Illumina, Inc.
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Cell Microsystems
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Greiner Bio One International GmbH
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Ikonisys Inc.
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Miltenyi Biotec
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives